Abstract
A new superamphiphile based cross-linked small-molecule micelle (SA-CSM) is developed for pH-triggered release of anticancer drugs. This strategy revolves around the use of a noncovalent superamphiphile formed by the elaborate zwitterion 1 and anticancer drug doxorubicin (DOX) via their “spontaneous attraction” of carboxylic acid and amino group. The superamphiphiles self-assemble into micelles in water, which were further stabilized by cross-linking the surface via the thiol-acrylate Michael addition to achieve the establishment of the pH-sensitive SA-CSMs. The biological evaluation shows that the new drug delivery system exhibits highly efficient anticancer efficacy both in vitro, on the HeLa cancer cell line, and in vivo, on the HeLa xenograft model, while suppressing the inherent toxicity of the employed chemotherapeutics. Compared with the reported covalent amphiphile based CSMs, the noncovalent superamphiphile based CSMs not only have comparable drug loading content (up to 45.0%), robust stability, ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
